The SELECT Trial in Plain English: Heart Benefit Without Diabetes

For years, GLP-1 trials showed heart benefits mostly as a secondary finding — and primarily in people with type 2 diabetes. The SELECT trial changed that framing. It was designed from the start to answer one specific question: does semaglutide reduce serious cardiovascular events in people who are overweight or obese but don't have diabetes?

The answer, published in the New England Journal of Medicine in November 2023, was yes — and the reduction was meaningful.

What SELECT was designed to test

SELECT stands for Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity. Unlike earlier cardiovascular outcome trials (CVOTs) that enrolled mostly people with type 2 diabetes, SELECT required participants to have:

• Established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease)
• BMI ≥ 27
• No diabetes at enrollment

That last criterion is what makes SELECT different. Previous GLP-1 CVOTs like LEADER (liraglutide) and SUSTAIN-6 (semaglutide) enrolled people managing blood sugar alongside their heart disease. SELECT stripped away the diabetes variable.

The trial enrolled 17,604 participants at 804 sites across 41 countries. Participants were randomized to weekly subcutaneous semaglutide 2.4 mg (the Wegovy dose) or placebo, on top of standard-of-care cardiovascular management. Median follow-up was about 40 months — just over three years.

The headline result: 20% MACE reduction

The primary outcome was MACE — a composite of:

1. Cardiovascular death
2. Non-fatal heart attack (myocardial infarction)
3. Non-fatal stroke

Semaglutide reduced MACE by 20% versus placebo (hazard ratio 0.80, 95% CI 0.72–0.90). That's a statistically robust result; the confidence interval doesn't cross 1.0, and the reduction held across all three components of the composite.

In absolute terms: for every 100 people treated with semaglutide for ~3.3 years (the median follow-up), roughly 1.5 serious cardiovascular events were prevented compared to placebo.

Why the result matters — and why it's not fully explained

Here's where the trial gets interesting: the MACE reduction appeared faster than the weight loss would predict. Cardiovascular events began diverging between the semaglutide and placebo groups within the first few months, before meaningful weight loss had accumulated.

This suggests the benefit isn't purely mediated by weight change. Researchers identified several candidate mechanisms:

• Blood pressure reduction — semaglutide consistently lowers systolic BP by 3–5 mmHg on average
• Anti-inflammatory effects — C-reactive protein (a marker of vascular inflammation) dropped significantly in the semaglutide group
• Lipid changes — modest reductions in triglycerides and LDL were observed
• Direct cardiac effects — GLP-1 receptors are expressed in cardiac tissue; the drug may have direct anti-inflammatory or cardioprotective effects

The trial wasn't designed to disentangle these mechanisms, so it can't tell us how much each one contributed. That's an important caveat for anyone trying to decide whether weight loss specifically is the goal.

What SELECT does not prove

A few things the trial results don't establish:

It's not a green light for everyone with heart disease. The enrolled population had established cardiovascular disease — meaning they'd already had a heart attack, stroke, or equivalent event. The results don't automatically extend to people with cardiovascular risk factors but no prior event. That's a different population.

It's not a comparison to competing therapies. SELECT compared semaglutide to placebo, not to other weight-loss or cardioprotective interventions. Whether semaglutide adds benefit on top of optimally dosed statins, ACE inhibitors, and other standard-of-care drugs in the specific context of a SELECT-like population isn't fully resolved.

All-cause mortality was not significantly reduced. SELECT was not powered to detect a mortality benefit as a primary endpoint. The numerical trend favored semaglutide, but the result didn't reach statistical significance.

The FDA response

In March 2024, the FDA approved Wegovy (semaglutide 2.4 mg) for reducing the risk of serious cardiovascular events in adults with established cardiovascular disease and obesity or overweight. This was an expanded label beyond the original weight-loss indication.

That means, for the first time, a GLP-1 drug can be prescribed with a cardiovascular protection justification independent of diabetes or weight loss goals. Whether insurance covers it on those grounds is a separate question — and coverage criteria are still evolving.

What it means for prescribing decisions

SELECT has shifted how many cardiologists and primary care physicians think about semaglutide. Before the trial, the conversation was: "Should we add a GLP-1 for your blood sugar or weight?" After SELECT, for patients with established cardiovascular disease and obesity, the conversation can be: "There's now a cardiovascular risk-reduction argument for this medication."

That doesn't make it automatic. The GI side effects, cost, and weekly injection burden are real. But SELECT gave clinicians a clearer risk-benefit calculation for a specific patient type.

For patients with heart disease who are overweight and either managing diabetes or not, it's worth having this conversation explicitly. The SELECT result is one of the more robust cardiovascular findings to come out of the GLP-1 era — not the only tool, but a meaningful one.

Related reading

• Semaglutide guide — how Ozempic and Wegovy work and what to expect
• Ozempic vs Wegovy — same molecule, different doses and indications
• GLP-1 side effects overview — what to watch for on any GLP-1 drug
• Weight loss timeline by month — how results typically progress